NOVEL SELECTIVE AROMATASE INHIBITING COMPOUNDS

PCT No. PCT/FI93/00539 Sec. 371 Date May 19, 1995 Sec. 102(e) Date May 19, 1995 PCT Filed Dec. 14, 1993 PCT Pub. No. WO94/13645 PCT Pub. Date Jun. 23, 1994New compounds of formula (I) wherein R1 is H, CH3, OCH3, NO2, NH2, CN, CF3, CHF2, CH2F or halogen, R2 is a heterocyclyl radical selected from 1-i...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	LAINE AIRE MARJA, SALONEN JARMO SAKARI, PELKONEN REINO OLAVI, SOEDERVALL MARJA-LIISA, KALAPUDAS ARJA MARKETTA, LAMMINTAUSTA RISTO ARVO SAKARI, KARJALAINEN ARTO JOHANNES
Format:	Patent
Sprache:	eng ; slv
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	PCT No. PCT/FI93/00539 Sec. 371 Date May 19, 1995 Sec. 102(e) Date May 19, 1995 PCT Filed Dec. 14, 1993 PCT Pub. No. WO94/13645 PCT Pub. Date Jun. 23, 1994New compounds of formula (I) wherein R1 is H, CH3, OCH3, NO2, NH2, CN, CF3, CHF2, CH2F or halogen, R2 is a heterocyclyl radical selected from 1-imidazolyl, triazolyl, tetrazolyl, pyrazolyl, pyrimidinyl, oxazolyl, thiazolyl, isoxazolyl and isothiazolyl, R3 is H or OH, R4 is H, R5 is H or OH; or R4 is H and R3 and R5 combined form a bond; or R3 is H and R4 and R5 combined form -(O); R6 is methylene, ethylene, -CHOH-, -CH2-CHOH-, -CHOH-CH2-, -CH-CH- or -C(-O)-; or R4 is H and R5 and R6 combined is -CH- or -CH-CH2-; stereoisomers thereof and non-toxic pharmaceutically acceptable acid addition salts thereof exhibit selective aromatase inhibiting properties, compared with their desmolase inhibiting properties. The compounds of the invention are valuable in the treatment of estrogen dependent diseases, e.g. breast cancer or benign prostatic hyperplasia (BPH).